Skip to main content

Table 2 Types of management changes and reasons for changes by arm for modified intention-to-treat cohort

From: The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis

Category

Scheduled Ab testing (n = 653)

Usual care (n = 577)

p-value

Number of patients who had a therapy change, n (%)

128 (19.6)

81 (14.0)

0.004

Type of therapy change, n (%)*,

   

Start glatiramer acetate

47 (7.2)

17 (2.9)

0.002

≥1 courses of corticosteroids for relapse

67 (10.3)

27 (4.7)

0.001

Reasons for therapy/management change, n (%) ‡,§

   

NAb result

45 (6.9)

3 (0.5)

<0.0001

Clinical composite

144 (22.1)

96 (16.6)

0.011

Other

35 (5.4)

16 (2.8)

0.011

  1. *Patients reporting a change in type of therapy one or more times were counted once at the earliest occurrence for the same category.
  2. Types of therapy change that were not significantly different between arms included: stop or increase or decrease current interferon beta (IFNβ), start new IFNβ, start other immunotherapy, change symptomatic therapy, and closer vigilance.
  3. Multiple reasons could be reported for one therapy change; however, patients reporting the same reason more than once were only counted once at the earliest occurrence.
  4. §Reasons for therapy change that were not significantly different between arms included: clinical worsening of multiple sclerosis, magnetic resonance imaging change, side effect, other concurrent illness/adverse event, laboratory abnormality, and administrative/logistical reason.
  5. Either clinical worsening or change on magnetic resonance imaging.
  6. Ab, antibody; NAb, serum neutralizing antibody.